The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000

References

• Westermark P. Classification of amyloid fibril proteins and their precursors: an ongoing discussion. Amyloid: Int J Exp Clin Invest 1997; 4: 216–218
   Web of Science ®Google Scholar
• Boyd W. A Textbook of Pathology: An Introduction to Medicine. Lea and Febiger, Philadelphia 1932; 107
   Google Scholar
• Bitter T, Muir H. Mucopolysaccharides of whole human spleens in generalized amyloidosis. J Clin Invest 1966; 45: 963–975
   PubMed Web of Science ®Google Scholar
• Snow A D, Kisilevsky R. A close ultrastructural relationship between sulphated proteoglycans and AA amyloid fibrils. Lab Invest 1988; 57: 687–698
   Google Scholar
• Inoue S, Kisilevsky R. A high resolution ultra-structural study of experimental murine AA amyloid. Lab Invest 1996; 74: 670–683
   PubMed Web of Science ®Google Scholar
• Ailles L, Kisilevsky R, Young I D. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993; 69: 443–448
   PubMed Web of Science ®Google Scholar
• Snow A D, Kisilevsky R, Stephens C, Anastassiades T. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Quantitative and qualitative analysis. Lab Invest 1987; 56: 665–675
   PubMed Web of Science ®Google Scholar
• McCubbin W D, Kay C M, Narindrasorasak S, Kisilevsky R. Circular dichroism and fluorescence studies on two murine serum amyloid A proteins. Biochem J 1988; 256: 775–783
   PubMed Web of Science ®Google Scholar
• De Beer M C, de Beer F C, McCubbin W D, Kay C M, Kindy M S. Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 1993; 268: 20606–20612
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Lemieux L J, Fraser P E, Kong X Q, Hultin P G, Szarek W A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat Med 1995; 1: 143–148
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Fraser P. Proteoglycans and amyloid fibrillogenesis. Ciba Foundation Symposium 1996; 199: 58–72
   PubMedGoogle Scholar
• Castillo G M, Cummings J A, Yang W H, Judge M E, Sheardown M J, Rimvall K, Hansen J B, Snow A D. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 1998; 47: 612–620
   PubMed Web of Science ®Google Scholar
• Ancsin J B, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999; 274: 7172–7181
   PubMed Web of Science ®Google Scholar
• Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell J R, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet 1999; 23: 354–358
   PubMed Web of Science ®Google Scholar
• Pepys M B, Booth D R, Hutchinson W L, Gallimore J R, Collins P M, Hohenester E. Amyloid P component. A critical review. Amyloid: Int J Exp Clin Invest 1997; 4: 274–295
   Web of Science ®Google Scholar
• Baltz M L, Caspi D, Evans D J, Rowe I F, Hind C RK, Pepys M B. Ciculating amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986; 66: 691–700
   PubMedGoogle Scholar
• Botto M, Hawkins P N, Bickerstaff M CM, Herbert J, Bygrave A E, McBride A, Hutchinson W L, Tennent G A, Walport M J, Pepys M B. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997; 3: 855–859
   PubMed Web of Science ®Google Scholar
• Danielsen B, Sorensen U, Nybo M, Nielsen E H, Kaplan B, Svehag S E. Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: Enhanced binding at slightly acid pH. Biochim Biophys Acta 1997; 1339: 73–78
   PubMedGoogle Scholar
• Hawkins P N, Richardson S, Macsweeney J E, King A D, Vigushin D M, Lavender J P, Pepys M B. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Quart J Med 1993; 86: 365–374
   PubMedGoogle Scholar
• Gallo G, Wisniewski T, Choi-Miura N H, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145: 526–530
   PubMed Web of Science ®Google Scholar
• Mahley R W, Huang Y D. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999; 10: 207–217
   PubMed Web of Science ®Google Scholar
• Bales K R, Verina T, Dodel R C, Du Y S, Altstiel L, Bender M, Hyslop P, Johnstone E M, Little S P, Cummins D J, Piccardo P, Ghetti B, Paul S M. Lack of apolipoprotein E dramatically reduces amyloid β peptide deposition. Nat Genet 1997; 17: 263–264
   PubMed Web of Science ®Google Scholar
• Kindy M S, Rader D J. Reduction in amyloid A amyloid formation in apolipoprotein-E- deficient mice. Am J Pathol 1998; 152: 1387–1395
   PubMed Web of Science ®Google Scholar
• Chan W, Fornwald J, Brawner M, Wetzel R. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide Aβ. Biochemistry 1996; 35: 7123–7130
   PubMed Web of Science ®Google Scholar
• Golabek A A, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid b-peptide is dependent on β-peptide conformation. J Biol Chem 1996; 271: 10602–10606
   PubMed Web of Science ®Google Scholar
• Biere A L, Ostaszewski B, Stimson E R, Hyman B T, Maggio J E, Selkoe D J. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271: 32916–32922
   PubMed Web of Science ®Google Scholar